Using light therapy to improve gum health in obese patients with periodontitis
Official title: Effects of Antimicrobial Photodynamic Therapy in Non-surgical Periodontal Treatment of Patients With Obesity
Run by University of Sao Paulo · NCT06073704 · Data updated 2026-11-12
This study is testing whether adding light therapy to regular gum treatment can help improve gum health in obese patients with gum disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 24 (estimated) |
| Sponsor | University of Sao Paulo Academic / other |
| Locations | 1 site (Bauru, São Paulo) |
| Status | Recruiting |
| Started | October 9, 2023 |
| Main results expected | July 30, 2026 |
| Study ends | December 30, 2026 |
| Registry record updated | May 4, 2026 |
| Trial ID | NCT06073704 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are obese individuals classified with grade II or III obesity who have stage II to IV periodontitis.
✕Probably not a fit
Patients who smoke, consume alcohol or drugs, or have certain medical conditions such as kidney disorders will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the effectiveness of adjunct antimicrobial photodynamic therapy (aPDT) in conjunction with scaling and root planing for treating periodontal disease in obese patients. Participants will be divided into two groups, one receiving standard treatment and the other receiving aPDT alongside the standard treatment. The study will assess improvements in periodontal health and analyze changes in the proteomic profile of gingival fluid over a period of 6 months. The goal is to determine if aPDT enhances treatment outcomes compared to traditional methods alone.
Why it matters
Potential benefit: If successful, this approach could lead to improved periodontal health outcomes for obese patients suffering from periodontitis.
How similar studies have gone: While the specific combination of aPDT and periodontal treatment in obese patients is novel, similar studies have shown promising results with aPDT in periodontal therapy.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Obesity (grade II and III classified according to Body Mass Index) * Periodontitis stage II to IV * Presence of at least 20 teeth excluding 3rd molars. Exclusion Criteria: * Smokers * Alcohol or drugs consumption * Kidney disorders * Pregnancy or lactation * Use of antibiotics at the last 30 days * Use of drugs that alter periodontal structures as phenytoin or ciclosporin * Periodontal treatment at the last 6 months
Where it's running
-
Bauru School of Dentistry
Bauru, São Paulo, Brazil Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ocular Changes in People Using Tirzepatide or Semaglutide
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Berobenatide for knee pain in adults who are overweight or with obesity
This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.
-
Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese
This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).
-
Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists
This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.